Hematology Frontier

From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the top international conferences in the oncology field, it brought together experts and scholars from around the world to share cutting-edge research findings and discuss future development directions. At this year's conference, a study led by Dr. Peng Liu's team from Zhongshan Hospital, Fudan University, was selected for a Mini Oral presentation, which was delivered on-site by Dr. Jiadai Xu. The study explored a chemotherapy-free first-line treatment approach for marginal zone lymphoma (MZL), with preliminary results proving promising. Hematology Frontier invited Dr. Xu for an in-depth discussion on the study and her expectations for the future of this treatment approach and research plans.

Autologous hematopoietic stem cell transplantation (ASCT) is a treatment option for adult acute leukemia in remission. Compared to allogeneic hematopoietic stem cell transplantation (allo-HSCT), ASCT has advantages such as no donor restrictions, absence of graft-versus-host disease (GVHD), and a lower transplant-related mortality rate. At the recent "4th Shanghai Symposium on the Clinical Application of Autologous Hematopoietic Stem Cell Transplantation," Dr. Aimang Pang from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, delivered an insightful presentation on the "Tianjin Model" for ASCT in treating acute leukemia. The highlights of the presentation are summarized here for our readers.

From September 6th to 8th, 2024, the 5th Tianjin International Lymphoma Academic Conference was successfully held. The conference featured 12 thematic sessions covering topics such as immunotherapy, translational research, and new drug development, creating a platform for promoting international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Ou Bai from The First Bethune Hospital of Jilin University to discuss the content of the Greater China region BTK Inhibitor Consensus on indolent lymphomas.

The 11th Sino-French Hematology Academic Conference, organized by the Chinese Medical Doctor Association, recently took place in Tianjin, drawing hundreds of leading experts and scholars in the field of hematology from around the world. During the conference, Hematology Frontier invited Dr. He Huang from The First Affiliated Hospital, Zhejiang University School of Medicine and Dr. Didier Blaise from the Hematology Institute of Aix-Marseille University in France to engage in a dialogue on the challenges and opportunities in new cellular therapies for hematologic malignancies. Here are the key insights from their conversation.

From September 13th to 17th, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's top oncology conferences, it brought together experts and scholars from across the globe to share cutting-edge research findings and discuss future directions. At the session dedicated to hematologic malignancies, Dr. Junyuan Qi from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the first-in-human study of the BCL-2 inhibitor TQB3909 in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) and acute myeloid leukemia (AML), showing promising results. Hematology Frontier invited Professor Qi to provide an in-depth analysis of the study and discuss the future clinical applications and research directions for this novel BCL-2 inhibitor.

From September 25-29, 2024, the "27th National Clinical Oncology Conference and 2024 CSCO Annual Meeting," hosted by the Chinese Society of Clinical Oncology (CSCO) and the Beijing Xisike Clinical Oncology Research Foundation, will be held in Xiamen. The conference, themed "Patient-Centered, Sharing the Future," brings together the latest research advancements and developments in the field, both domestically and internationally. For more than 20 years, CSCO has been at the forefront of clinical oncology in China, with experts deeply involved in its growth, advancing their careers through this platform. Hematology Frontier has launched a special "Growing with CSCO" series, inviting Chinese scholars to revisit past stories. In this issue, we invited Dr. Ou Bai, a member of the CSCO United Committee for Lymphoma Intervention (UCLI) and a key figure in the development of the lymphoma specialty at The First Bethune Hospital of Jilin University, to share the story of growing together with CSCO.

From September 13 to 17, the 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. As one of the world's leading oncology events, experts and scholars from across the globe gathered to share cutting-edge research results and explore future development directions. In the Mini Oral session on hematologic malignancies, Dr. Zhiming Li from the Sun Yat-sen University Cancer Center presented the results of a phase I/II study on the combination of chidamide and mitoxantrone hydrochloride liposome in the treatment of relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This study offers new options to improve the prognosis of R/R PTCL patients and contributes a promising Chinese strategy to the global development of hematologic oncology. Hematology Frontier invited Professor Li to provide an in-depth analysis of the study and share his expectations for future research on this combination therapy.

From September 6 to 8, 2024, the 5th Tianjin International Lymphoma Conference was grandly held, attracting global experts to foster academic exchange and cooperation. During the conference, Hematology Frontier invited Dr. Peiqi Zhao from Tianjin Medical University Cancer Institute and Hospital to discuss the latest advances in follicular lymphoma treatment and the evolving concept of comprehensive disease management.

The 5th Tianjin International Lymphoma Conference was successfully held from September 6 to 8, 2024. The conference featured 12 specialized sessions, including immunotherapy, basic translational research, and new drug development, providing a platform for international academic exchange and collaboration. During the event, Hematology Frontier invited Dr. Xiubao Ren from Tianjin Medical University Cancer Institute and Hospital to share insights on the progress of clinical trials in reverse immune editing therapy and its future application prospects in cancer treatment.

From September 13 to 17, 2024, the European Society for Medical Oncology (ESMO) Annual Meeting is being held in Barcelona, Spain. As one of the top international oncology conferences, the event gathers experts and scholars from around the world to share cutting-edge research and discuss future developments. In the Mini Oral Session on Hematologic Malignancies, Dr. Ling Pan from West China Hospital, Sichuan University, presented a pivotal phase II study comparing rovatirelinib with hydroxyurea for the treatment of intermediate and high-risk myelofibrosis (MF). The results demonstrated significant benefits in both efficacy and safety for rovatirelinib, offering a new potential treatment option for MF patients. Hematology Frontier invited Dr. Ling Pan to discuss the current landscape and challenges in the diagnosis and treatment of MF, provide insights into this pivotal study, and share her experiences at the ESMO conference.